SSTR2 and acromegaly: Additionally, somatostatin receptor type two (SSTR2) expression, which was long-acting somatostatin analogs widely used to treat acromegaly, was nearly two-fold higher in invasive (217.7 ± 19) than those in non-invasive samples (108 ± 27.2, p < 0.01; Figures 2A,B).